Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in relapsed/refractory acute myeloid leukemia: results of a pilot study

• Yan-Yan Li,
• Shuai-Shuai Ge,
• Yuan-Hong Huang,
• Ming-Zhu Xu,
• Chao-Ling Wan,
• Kai-Wen Tan,
• Tao Tao,
• Hai-Xia Zhou,
• Sheng-Li Xue,
• Hai-Ping Dai

Affiliations

Yan-Yan Li

National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University

Shuai-Shuai Ge

National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University

Yuan-Hong Huang

National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University

Ming-Zhu Xu

National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University

Chao-Ling Wan

National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University

Kai-Wen Tan

National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University

Tao Tao

Department of Respiratory and Critical Medicine, The Affiliated Infectious Diseases Hospital of Soochow University

Hai-Xia Zhou

National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University

Sheng-Li Xue

National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University

Hai-Ping Dai

National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University